# FILSPARI
> **NDA216403** · New Drug Application · Sponsor: TRAVERE · Approved 2023-02-17
## Drug
- **FDA Application Number:** NDA216403
- **Application type:** New Drug Application
- **Brand name:** FILSPARI
- **Generic name:** SPARSENTAN
- **Active ingredients:** SPARSENTAN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** TRAVERE
- **Manufacturer:** Travere Therapeutics, Inc.
- **First approval:** 2023-02-17
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216403)
---
*AI Analytics · CC0 1.0*